PIPELINE

Providing answers at every step of lung cancer patient assessment

*Available for enrolling sites for our clinical utility study

Percepta® Nasal Swab

PERCEPTA® NASAL SWAB

What is the test?

Objective tools are needed to assess the risk of lung cancer in patients with detected lung nodules

Approximately 1.6 million lung nodules are detected every year with many requiring further evaluation to distinguish between malignant and benign.¹

What is Percepta Nasal Swab?

It is a first-of-its-kind, office-based genomic test that objectively classifies lung cancer risk in an identified lung nodule of patients that are ever-smokers. The test result can provide guidance on which patients can safely avoid unnecessary invasive procedures or undergo further workup to confirm their diagnosis.

Percepta Nasal Swab uses a simple and convenient nasal brushing to objectively evaluate suspicious lung nodules

~44% of low-risk patients underwent an invasive procedure to evaluate a lung nodule that was found to be benign.²

~50% of lung cancer patients receive 2 or more biopsies, delaying the time to diagnosis.³

Sample collection

A simple nasal swab brushing just past the inferior nasal turbinate is used to collect a sample, which is sent to Veracyte.

Test results

Low risk

Monitor with low dose CT

Moderate risk

Consider non-surgical tissue sampling inclusive of bronchoscopy

High risk

Consider sending patients for direct surgery and/or treatment

Percepta Genomic Atlas evidence

ASCO 2022 Abstract Publication

Molecular profiling of dedicated lung cancer biopsy tissue sample collected at time of diagnostic bronchoscopy

ASCO 2022: This Veracyte abstract demonstrates that Percepta Genomic Atlas detects the clinically actionable mutations in patients with non-small cell lung cancer using fresh tissue specimens collected during bronchoscopic tissue sampling, with high concordance to standard of care testing.

The Percepta Nasal Swab test is currently available to select sites as part of a clinical utility study.

Contact us if you’d like to discuss or learn more about Percepta Nasal Swab.

Percepta® Genomic Atlas

PERCEPTA® GENOMIC ATLAS

What is the test?

Treating lung cancer with appropriate targeted therapies can improve outcomes

Guidelines recommend broad tumor profiling for appropriate patients with metastatic non-small cell lung cancer. Despite these recommendations, more than 50% of lung cancer patients are not tested for recommended biomarkers.⁴

What is Percepta Genomic Atlas?

Percepta Genomic Atlas is a DNA/RNA next generation sequencing (NGS) tissue-based assay that identifies genomic alterations with a focus on lung cancer related genes.